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Acinetobacter baumannii, Acinetobacter nosocomialis, and
Acinetobacter pittii are a frequent cause of multidrug-resistant,
healthcare-associated infections. Our previous work demon-
strated that A. nosocomialis M2 possesses a functional type II
secretion system (T2SS) that is required for full virulence. Fur-
ther, we identified the metallo-endopeptidase CpaA, which has
been shownpreviously to cleave humanFactorV and deregulate
blood coagulation, as the most abundant type II secreted effec-
tor protein. We also demonstrated that its secretion is depen-
dent on CpaB, a membrane-bound chaperone. In this study, we
show that CpaA expression and secretion are conserved across
several medically relevant Acinetobacter species. Additionally,
we demonstrate that deletion of cpaA results in attenuation of
A. nosocomialis M2 virulence in moth and mouse models. The
virulence defects resulting from the deletion of cpaAwere com-
parable with those observed upon abrogation of T2SS activity.
The virulence defects resulting from the deletion of cpaA are
comparable with those observed upon abrogation of T2SS activ-
ity. We also show that CpaA and CpaB strongly interact, form-
ing a complex in a 1:1 ratio. Interestingly, deletion of the N-
terminal transmembrane domain of CpaB results in robust
secretionofCpaAandCpaB, indicating that the transmembrane
domain is dispensable forCpaA secretion and likely functions to
retain CpaB inside the cell. Limited proteolysis of spheroplasts
revealed that the C-terminal domain of CpaB is exposed to the
periplasm, suggesting that this is the site where CpaA and CpaB
interact in vivo. Last, we show that CpaB does not abolish the
proteolytic activity of CpaA against human Factor V. We con-
clude that CpaA is, to the best of our knowledge, the first char-
acterized, bona fide virulence factor secreted by Acinetobacter
species.
Bacterial protein secretion is one way in which cells interact
with and impact their environment. For instance, toxins and
hydrolytic enzymes secreted by the type II secretion system
(T2SS)6 aid in nutrient acquisition and promote in vivo survival
and virulence of several pathogens, including Vibrio cholerae,
enterotoxigenic Escherichia coli, Pseudomonas aeruginosa, and
Legionella pneumophila (1–7). The T2SS is composed of an
outer membrane secretin, a periplasmic pseudopilus, an inner
membrane platform, and a cytoplasmic ATPase, and it is wide-
spread among pathogenic and non-pathogenic Gram-negative
bacteria (8–11). Secretion through the T2SS is a two-step pro-
cess. First, type II substrates are translocated from the cytosol to
the periplasmic space by either the general secretory (Sec) path-
way or the Twin-arginine translocation (Tat) system (10, 11).
Then, folded type II substrates are pushed through the outer
membrane secretin and into the extracellular space via pseudo-
pilus polymerization. Although type II substrates associatewith
the secretion apparatus through interactions with the outer
membrane secretin, components of the inner membrane plat-
form, and/or components of the pseudopilus, including the
major pseudopilin and theminor pseudopilins (12–14), it is not
well-understood how type II substrates are targeted to the type
II secretion apparatus and differentially recognized relative to
other fully folded soluble periplasmic proteins (12).
Acinetobacter baumannii is among the most threatening
multidrug-resistant nosocomial pathogens worldwide. In fact,
the World Health Organization has recently categorized it as a
critical priority for the research and development of new anti-
biotics (15). However, it is important to highlight that the entire
Acinetobacter calcoaceticus–A. baumannii complex, which is
comprised primarily of A. baumannii, Acinetobacter nosoco-
mialis, A. calcoaceticus, and Acinetobacter pittii, is becoming
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an increasing medical concern (16, 17). In addition to being
extensively drug-resistant, Acinetobacter species (spp.) are
capable of forming biofilms and withstanding desiccation as
well as a wide range of temperatures and pH values (18–22).
Altogether, these features allow Acinetobacter to persist in
healthcare facilities, where it is a frequent cause of infections
such as ventilator-associated pneumonia and bacteremia
(23–25).
The presence of T2SS components inA. baumanniiwas first
reported in 2014 (26). Subsequently, Johnson et al. (27) showed
that the T2SS ofA. baumanniiATCC 17978, a commonly used
laboratory strain, is active. Type II–dependent secretion of
LipA is required for growth in minimal medium supplemented
with long-chain fatty acids as the sole carbon source, indicating
an important role in nutrient acquisition (27). Furthermore, the
T2SS and T2SS-dependent lipid utilization are required for
competitive colonization of a neutropenic murine model of
infection (27).
Recently, through heterologous expression and secretion of
A. nosocomialis M2 (formerly A. baumannii M2) T2SS sub-
strates, we demonstrated that A. baumannii 19606, A. nosoco-
mialis M2, A. pittii, A. calcoaceticus, and Acinetobacter junii
also possess a functional T2SS (28). Proteomic comparison of
supernatants from wild-type A. nosocomialis M2 and an outer
membrane secretin gspD mutant revealed numerous putative
substrate proteins, all with predicted N-terminal Sec signals
(28). Three of these substrates, the protease CpaA and the
lipases LipA and LipH, were confirmed as T2SS substrates.
CpaA was shown previously to be a secreted zinc-dependent
metallo-endopeptidase that is capable of degrading fibrinogen
and Factor V, thus deregulating blood coagulation (29). Impor-
tantly, the T2SS ofA. nosocomialis is required for full virulence
in Galleria mellonella and pulmonary murine models of infec-
tion (28). Although the wild-type and complemented strains
efficiently disseminate to the liver or spleen after intranasal
infection, the T2SS-deficient strain does not disseminate as
efficiently, suggesting that the T2SS ofA. nosocomialis plays an
important role in virulence. However, the contribution of spe-
cific T2SS substrates in virulence has not been investigated.
Similarly to the P. aeruginosa type II metallo-protease elas-
tase (34), two Acinetobacter T2SS substrates, LipA and CpaA,
were found to require chaperones, LipB and CpaB respectively,
for their secretion (28). However, unlike elastase, which is pro-
duced as a preproelastase, where the prodomain functions as an
intramolecular chaperone (30, 31), LipB and CpaB are encoded
adjacently to their cognate effector proteins and are predicted
to be membrane-bound. CpaB and LipB have no sequence or
predicted structural domain similarities (28). Topological pre-
diction servers and bioinformatic analysis of LipB and CpaB
suggest that their N-terminal transmembrane domains are
imbedded in the innermembrane, with theC-terminal globular
portions present in the periplasm (28). CpaB andLipB appear to
be specific for CpaA and LipA, respectively, and none of these
chaperones are required for the secretion of LipH (28). LipB is
functionally similar to the Burkholderia glumae type II secre-
tion membrane-bound chaperone lipase-specific foldase (Lif),
which is required for the production of enzymatically active
lipase. The function of the transmembrane domain of Lif is
unclear, as this domain was not required for the steric chaper-
one activity of Lif (32–34). It has been proposed that CpaB,
LipB, and Lif belong to a novel class of chaperones collectively
known as T2SS chaperones (28). The involvement of chaper-
ones in type II secretion is reminiscent of type III secretion
systems (T3SSs), where the chaperones are soluble cytoplasmic
proteins that interact with a specific substrate or multiple sub-
strates and aid in folding, stabilization, and/or regulation of the
secretion of these substrates (35). However, unlike T3SS chap-
erones, T2SS chaperones do not present any sequence homo-
logy and are variable in size and isoelectric point. To our knowl-
edge, CpaB is the first reported membrane-bound, periplasmic
chaperone required for secretion of a type II protease.
In this study, employing a combination of mutational and
biochemical methods, we investigated the role of CpaA in
A. nosocomialis pathogenesis and characterized the interaction
between CpaA and its T2SS chaperone CpaB.We demonstrate
that CpaA is required for virulence againstG. mellonella larvae
and is required for dissemination of A. nosocomialis to the
spleen in amurine pulmonarymodel of infection. Furthermore,
we show that CpaA and CpaB strongly interact and that the
C-terminal periplasmic domain of CpaB is sufficient for chap-
erone function and interaction with CpaA. Last, we demon-
strate that CpaB binding is incapable of blocking the proteolytic
activity of CpaA against human Factor V.
Results
CpaA is secreted bymedically relevant Acinetobacter species
The metallopeptidase CpaA is the most abundantly secreted
type II substrate in A. nosocomialis strain M2 (28). Although
older isolates such as A. baumannii ATCC 17978 and ATCC
19606 do not encode cpaA, the cpaA gene is conserved across
clinical isolates of A. baumannii (29). However, it is unknown
whether CpaA is secreted by these strains. To determine the
prevalence of CpaA secretion among recent clinical isolates of
medically relevant Acinetobacter strains, we generated a spe-
cific polyclonal antibody against CpaA (see “Experimental pro-
cedures” and supplemental Fig. S1). The anti-CpaA antibody
was employed to screen variousA. baumannii,A. nosocomialis,
andA. pittii strains for CpaA expression and secretion. CpaA is
present in the supernatant of most of these recent isolates but
not in the supernatant of older laboratory strains (Fig. 1). Fur-
thermore, all strains that expressed CpaA secreted the protein.
Interestingly, there seems to be strain-to-strain differences in
the secretion efficiency of CpaA, suggesting possible differ-
ences in the regulation of CpaA secretion. The prevalence of
this metallo-peptidase among medically relevant clinical iso-
lates prompted us to investigate the contribution of CpaA to
Acinetobacter pathogenesis.
CpaA is required for optimal virulence in G. mellonella larvae
We showed previously that the T2SS of A. nosocomialisM2
is required for virulence in G. mellonella larvae (28). However,
we did not identify the specific substrate(s) responsible for this
phenotype. Because CpaA is themost abundant T2SS substrate
under laboratory conditions, and because it is secreted bymany
recently isolated strains, we tested the contribution of CpaA to
virulence inG. mellonella. First, we generated a strain contain-
Interaction between CpaA and chaperone CpaB














ing an unmarked deletion in cpaA (cpaA) and its correspond-
ing complemented strain by inserting a copy of the cpaAB locus
under its native promoter into the chromosome (cpaA)
downstream of glmS2 (36, 37). We analyzed the supernatant
fractions of wild-type A. nosocomialisM2, cpaA, and cpaA
byWestern blot analysis. As expected, the strain devoid of cpaA
did not secrete CpaA. However, CpaA secretion was restored
upon complementation by inserting cpaAB in the chromosome
ofM2cpaA (supplemental Fig. S1). Deletion of cpaA and cpaB
does not alter secretion of the type II substrate LipH, suggesting
that CpaB is specific for CpaA and does not broadly impact type
II secretion (supplemental Fig. S2).
G. mellonella larvae were infected with wild-type M2,
cpaA, or cpaA (see “Experimental procedures”), and sur-
vival wasmonitored over time (Fig. 2). ThegspD strain carries
a deletion in the gspD gene that inactivates T2SS and therefore
does not secrete any T2SS substrates (28). gspD and its corre-
sponding complemented strain (gspD) were included for
comparison purposes. Twenty-four hours post-infection, 50%
of larvae infected with either gspD or cpaA survived,
whereas infection with wild-type M2, gspD, or cpaA
resulted in less than 25% survival (Fig. 2). The difference in
percent survival of larvae infected with either gspD or cpaA
relative to the wild type or the complemented strains is statis-
tically significant (Fig. 2). Therefore, deletion of cpaA results in
a virulence defect in G. mellonella larvae comparable with the
T2SS mutation, suggesting that CpaA is the most important
T2SS substrate contributing to the virulence ofA. nosocomialis
M2.
CpaA aids in A. nosocomialis dissemination to the spleen in
mice
To further confirm the role of CpaA in a mammalian model
of infection,we infectedmice intranasallywith eitherwild-type,
cpaA, or the cpaA complemented strain. Thirty-six hours
post-infection, the lungs and spleen were harvested and ana-
lyzed for colony-forming units. Although no significant differ-
ence was observed, comparison of the bacterial burden in the
lungs of infected mice shows a trend toward decreased coloni-
zation by the cpaA strain relative to the wild-type and com-
plemented strains (Fig. 3A). In contrast, a statistically signifi-
cant difference was observed in the bacterial burden in the
spleens of mice infected with cpaA compared with mice
infected with the complemented strain (Fig. 3B). Furthermore,
we confirmed that deletion of both CpaA and CpaB did not
affect secretion of other T2SS substrates such as LipH (supple-
mental Fig. S2). Thus, CpaA appears to play a role in dissemi-
nation from the initial site of infection in the lungs to a distal
site in the spleen.
CpaA physically interacts with its dedicated chaperone CpaB
We showed previously that CpaA secretion is dependent on
an uncharacterized protein encoded immediately downstream
Figure 1. CpaA secretion is conserved among medically relevant Acinetobacter species. Whole cells (W) and supernatants (S) of A. baumannii (AB),
Acinetobacter baylyi (AY), A. calcoaceticus (AC), A. pittii (AP), and A. nosocomialis (AN) strains were analyzed by Western blotting using anti-CpaA (green) and
anti-RNA polymerase (red) antibodies. CpaA is detected in the supernatants of various AB, AP, and AN strains, all of which are recent clinical isolates. RNA
polymerase was included as a lysis control.
Figure 2. Type II secretion and CpaA are similarly required for full viru-
lence in the G. mellonella infection model. G. mellonella larvae were
injected with 10l of either M2,gspD,cpaA, or the complemented strains
at an inoculum of 1  107. Infected larvae were incubated at 37 °C and
monitored for viability over time. Viability was determined by melanin accu-
mulation and mobility. Larvae infected with gspD or cpaA had50% sur-
vival at 24 h. 25% of the larvae infected with M2 survived after 24 h. Larvae
infectedwith thegspD orcpaA complemented strains had 17% survival at
24 h post-infection. The difference in percent survival of larvae infected with
gspD or cpaA relative to the wild-type or complemented strains is statisti-
cally significant (Mantel Cox p 0.0447).
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of CpaA (28). We designated this protein CpaB because of its
proximity to cpaA. Domain-enhanced lookup time accelerated
(DELTA) BLASTp analysis identified a SRPBCC superfamily
domain in CpaB (28). Because proteins with a SRPBCC domain
are predicted to have a deep hydrophobic ligand-binding
pocket and chaperone-like activity, we postulated that CpaB
belongs to a new family ofmembrane-bound chaperones (T2SS
chaperones) that mediate the secretion of specific T2SS sub-
strates (28). T2SS chaperones could facilitate folding, inhibit
self-damaging activities by functioning as immunity proteins,
and/or pilot the secretion of their cognate substrates. All of
these activities require the interaction of the chaperone with it
is substrate. The physical interaction between CpaB and CpaA
was addressed through a pulldown assay. cpaA containing a
C-terminal FLAG tag and cpaB containing a C-terminal hexa-
histidine tag were both cloned into vector pWH1266 (pWH-
cpaA-flag-cpaB-his) and expressed inM2 cpaAB, which lacks
the endogenous cpaA and cpaB genes. Nickel-NTA affinity
chromatography was performed on cell lysate solubilized with
0.01% Triton X-100. CpaA-FLAG and CpaB-His were detected
by Western blot analysis in the load fraction, indicating that
both proteins were expressed (Fig. 4A, left). Despite not detect-
ing CpaA-FLAG in the wash fractions, CpaA-FLAG was
detected upon elution of immobilized CpaB-His (Fig. 4A).
Moreover, nickel-NTA affinity chromatography on cell lysate
from M2 cpaAB-expressing cpaA-flag and untagged cpaB
(pWH-cpaA-flag-cpaB) revealed that CpaA-FLAG is not eluted
in the absence of hexahistidine-tagged CpaB (Fig. 4B), indicat-
ing that CpaA binds specifically to CpaB. Further, Coomassie
staining of the elution from M2 cpaAB pWH-cpaA-flag-
cpaB-his lysate suggests that CpaA and CpaB associate specifi-
cally in an approximate 1:1 ratio (Fig. 4A, right).
We evaluated the stoichiometry of the CpaA–CpaB complex
by size-exclusion chromatography and sedimentation equilib-
rium analytical centrifugation (Fig. 5). Size-exclusion chroma-
tography of the co-purified complex of CpaA and a transmem-
brane-truncated CpaB resulted in an aggregate peak starting at
a void volume of 40ml and a complex peak at a volume of 85ml
(Fig. 5A). An SDS-PAGE gel of the complex peak showed two
bands corresponding to CpaA and CpaB and was consistent
with a 1:1 complex (Fig. 5B). To unambiguously determine the
molecular weight of the complex in solution, we used sedimen-
tation equilibrium analytical centrifugation, as this method can
determine the mass of complexes in solution independent of
shape. Sedimentation equilibrium analytical centrifugation of
the complex peak (Fig. 5C) revealed a molecular mass of 83.7
kDa 4.7 kDa using a one-component idealmodel to assess the
molecularmass of the complex in solution (38). The theoretical
molecular masses of CpaA and truncated CpaB are 63.1 kDa
and 20.4 kDa, respectively. A 1:1 complex of the CpaA and
CpaB therefore has a theoretical molecular mass of 83.5 kDa,
and the sedimentation equilibrium experiment aligns well with
the theoretical molecular mass of a 1:1 complex.
The C-terminal domain of CpaB faces the periplasmic space,
and its N-terminal transmembrane domain is not required for
CpaA secretion
Topological prediction servers and bioinformatic analysis
suggest that CpaB has an N-terminal transmembrane domain
(28, 29). Therefore, it is likely the C-terminal domain of CpaB
that interacts withCpaA. In vivo, this interaction could occur in
either the cytoplasm or the periplasm. To determine the cell
localization of the C-terminal domain of CpaB, we used limited
proteolysis of either whole cells or spheroplasts containing
CpaB-His, where the hexahistidine tag was added to the C ter-
minus (32, 39). Samples were visualized by Western blot anal-
ysis probing for CpaB-His and RNA polymerase as a cytoplas-
mic control. Whole cells treated with proteinase K have
consistent levels of CpaB-His and RNA polymerase over time
(Fig. 6A), indicating that CpaB-His is inaccessible to the prote-
ase. In contrast, spheroplasts treated with proteinase K show
decreasing levels of CpaB-His over time, suggesting that the
C-terminal domain is accessible to the protease (Fig. 6B). Fur-
thermore, the consistent levels of RNA polymerase over time
indicate that cytoplasmic proteins were sheltered from prote-
olysis (Fig. 6B). Altogether, these results show that the C termi-
nus of CpaB is periplasmic and suggest that CpaB interacts with
CpaA in the periplasm.
To determine whether the N-terminal transmembrane
domain of CpaB is required for CpaA secretion, we constructed
a soluble periplasmic version of CpaB (CpaBpelB-His) by replac-
ing the putative N-terminal transmembrane domain of CpaB-
Figure 3. CpaA aids in colonization of the spleen inmice.Micewere intra-
nasally inoculated with 1  109 cfus of either wild-type, cpaA, or the cpaA
complemented strain. 36 h post-infection, mice were sacrificed, organs were
harvested, and colony-forming units were enumerated from homogenized
tissue. A, total colony-forming units from the lung demonstrate a non-statis-
tically significant trend toward decreased colonization by the cpaA strain
(Kruskal-Wallis non-parametric, p 0.06). B, total colony-forming units from
the spleen demonstrate a statistically significant difference between the
complemented cpaA strain and thecpaAmutant strain (Kruskal-Wallis non-
parametric, *p 0.0327).
Figure 4. CpaA and CpaB strongly interact physically. A and B, Western
blot analysis of nickel affinity purifications from cell lysates of M2 cpaAB
expressing either pWH-cpaA-flag-cpaB-his (A) or pWH-cpaA-flag-cpaB (B).
Note that, in B, CpaB does not contain a C-terminal hexahistidine tag. CpaA-
FLAG was detected using an anti-FLAGmonoclonal antibody, whereas CpaB
was detected using anti-histidine polyclonal antibodies. The right panel in A
shows Coomassie-stained SDS-PAGE of the elution from A and thus repre-
sents the CpaA–FLAG–CpaB–His complex. L, loaded cell lysate, FT, flow-
through,W1–3, washes one to three; E, elution.
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Hiswith the Sec secretion signal of the periplasmic protein PelB
from Escherichia coli. As expected, CpaBpelB-His localized to
the periplasm (supplemental Fig. S3).We then transformedM2
cpaAB with FLAG-tagged CpaA and either full-length CpaB-
His or CpaBpelB-His and probed for the presence of CpaA in
cell-free supernatants. CpaA secretion was complemented by
either full-length CpaB-His or soluble periplasmic CpaBpelB-
His (Fig. 7), indicating that CpaB does not need to be mem-
brane-bound to mediate CpaA secretion. Interestingly, soluble
CpaB-His was also detected in cell-free supernatants of cells
expressing CpaA-FLAG (Fig. 7). To determine whether secre-
tion of the soluble periplasmic chaperone CpaB was CpaA-de-
pendent, we compared secretion of soluble CpaB-His in the
presence or absence of CpaA byWestern blotting (supplemen-
tal Fig. S4). In the absence of CpaA, secretion of soluble CpaB
was abrogated, suggesting that soluble periplasmic CpaB is
secreted in complex with CpaA (Fig. 6 and supplemental Fig.
S4). The minimal amount of soluble CpaB that was secreted in
the absence of CpaA could be a consequence of overexpression
of soluble CpaB.
CpaA is degraded in the absence of CpaB
CpaA is hard to detect in the periplasmic fraction because its
secretion is extremely efficient in wild-type A. nosocomialis
M2. In acpaB strain, CpaAwas not secreted and, instead, was
degraded in the periplasm, as indicated by aCpaA-derived band
of30 kDa present under these conditions (supplemental Fig.
S5). CpaB complementation restored CpaA secretion with the
subsequent disappearance of the CpaA proteolytic fragment.
This experiment demonstrates that CpaA is not stable in the
absence of CpaB.
CpaB interaction with CpaA does not completely abolish
proteolytic activity against Factor V
CpaA physically interacts with CpaB, and this interaction is
required for CpaA secretion (Fig. 4) (28). However, the specific
role of CpaB in CpaA secretion remains unclear. CpaA was
shown previously to be a secreted metallo-endopeptidase with
the ability to degrade human Factor V and thus deregulate
blood coagulation (29). One possibility is that this interaction
inactivates CpaA, preventing self-intoxication of the cell by the
proteolytic activity of CpaA (40). To explore the possibility that
CpaB is an immunity protein, we compared the proteolytic
activity of CpaA alone and in complex with the soluble version
of CpaB against human Factor V.
CpaA-His was purified from the cell-free supernatant of
mid-log phase A. nosocomialis M2, whereas the complex
CpaA-FLAG-CpaBpelB-His was purified from the supernatant
of A. nosocomialisM2cpaAB. For the complex, the hexahisti-
dine tag was placed in CpaB and not in CpaA to ensure that all
of the purified CpaA was complexed to CpaB. Cleavage of
human Factor V was analyzed byWestern blotting, probing for
human Factor V and CpaA. Interestingly, CpaA was able to
cleave Factor V irrespective of the presence of CpaB (Fig. 8). In
contrast, neither heat-inactivated CpaA nor CpaB alone could
cleave Factor V (Fig. 7). Although we have not followed the
kinetics of this reaction, it can be concluded that CpaB does not
completely inhibit CpaA activity against Factor V.
Discussion
CpaA is a zinc-dependent metallo-endopeptidase and T2SS
substrate of several medically relevant Acinetobacter strains
(28, 29). Although it is the most abundantly secreted type II
substrate in A. nosocomialis M2, CpaA is not present in the
genomes of typical Acinetobacter laboratory strains such as
ATCC17978 and ATCC19606 (28). Acinetobacter often pres-
Figure 5. CpaA and CpaB form a 1:1 complex in solution. A, size-exclusion chromatography of co-purified CpaA and CpaB reveals a single peak for the
CpaA–CpaB complex.mAu, milli-absorbance unit. B, SDS-PAGE gel of the CpaA–CpaB complex peak reveals two bands that correspond to CpaA and CpaB. C,
sedimentation equilibriumanalytical centrifugation of the size-exclusion–purifiedCpaA–CpaB complex reveals a 1:1 complex of 83.7 kDa 4.7 kDa. Top panel,
one-component ideal model fits for one representative experiment of three. Bottom panel, the residuals for the one-component ideal model fits for each
individual scan.
Figure 6. The C-terminal domain of CpaB is exposed to the periplasmic
space. Shown is a Western blot analysis probing for RNA polymerase as a
cytoplasmic control and CpaB-His of samples treatedwith 0.5g/ml protein-
ase K for 0–20min at 56 °C.A, limitedproteolysis ofM2whole cells expressing
pWH-cpaB-his. B, limited proteolysis of spheroplasts isolated from M2 cells
expressing pWH-cpaB-his.
Figure 7. Soluble periplasmic CpaB complements acpaBmutant and is
secretedwith CpaA. Shown is aWestern blot analysis on whole-cell (W) and
cell-free supernatant (S) fractions of cpaAB M2 expressing empty vector.
pWH-cpaB-his and pBAV-cpaA-flag or pWH-cpaBpelB-his and pBAV-cpaA-flag
were probed for CpaB-His. All fractions were probed for RNA polymerase as a
lysis control. CpaB-His was detected in all cells carrying pWH-cpaB-his or
pWH-cpaBpelB-his. Secretion of CpaB-His was detected in cells carrying pWH-
cpaBpelB-his. CpaA* is a degradation product from CpaA-FLAG.
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ents as pneumonia; therefore, a murine pulmonary infection
was used to study the role of CpaA in lung colonization and
dissemination.We showed previously that the T2SS ofA. noso-
comialisM2was required for full virulence inG. mellonella and
pulmonary murine models of infection (28). The T2SS-defi-
cient strain did not disseminate to the liver or spleen as effi-
ciently as the wild-type or complemented strains, suggesting
that substrates secreted by the T2SS play an important role in
Acinetobacter virulence. Herewe show that CpaA is secreted by
multiple clinical isolates ofA. baumannii,A. pittii, andA. noso-
comialis. Deletion of cpaA results in a virulence defect in
G. mellonella larvae and decreased splenic colonization in a
murine pulmonary infection model. The virulence defects
resulting from the deletion of cpaA are comparable with those
observed from the deletion of the T2SS. To our knowledge,
CpaA is the first characterized, bona fide virulence factor
secreted by Acinetobacter spp.
Numerous proteins are secreted by A. nosocomialis M2 in a
type II-dependentmanner (28). Asmentioned, deletion of cpaA
has a similar impact on murine splenic colonization and viru-
lence against G. mellonella as the loss of type II secretion
(gspD) (Fig. 3). However, unlike the gspD strain, the cpaA
strain did not show decreasedmurine lung colonization (Fig. 3)
(28). This discrepancy could be attributed to the loss of secre-
tion of all type II substrates in the gspD strain compared with
the single deletion of CpaA in the cpaA strain. LipA, a con-
firmed Acinetobacter type II substrate, is required for A. bau-
mannii competitivemurine colonization in a bacteremiamodel
(27). Therefore, it is plausible that LipA plays a role in murine
lung colonization by A. nosocomialis and, thus, may partly
account for the difference in colonization defect between the
gspD and cpaA strains. Moreover, CpaA may play a role in
dissemination from the initial site of infection in the lungs to a
distal site in the spleen. The activity of CpaA against the coag-
ulation factors fibrinogen and Factor V likely contributes to the
defect in cpaA to migrate from the initial infection site.
CpaA is likely translocated to the periplasm by the SecYEG
translocation system in an unfolded state (41). When in the
periplasm, CpaA must fold to be secreted by the T2SS (8, 42).
CpaB is a membrane-anchored protein encoded next to CpaA
and is required for CpaA secretion. This is reminiscent of the
B. glumae type II substrate LipA, which requires a membrane-
bound, lipase-specific foldase to be folded into its active form
and secreted (33, 34). In this work, we identified additional
functional similarities between CpaB and the Lif proteins. We
demonstrated that CpaB physically interacts with CpaA. Fur-
thermore, similarly to Lif, the C-terminal globular domain of
CpaB is periplasmic and sufficient for CpaA secretion (Fig. 7)
(34). Although both chaperones are required for secretion of
their cognate substrates, the transmembrane domains of both
Lif and CpaB are dispensable for the secretion and proper folding
of their respective protein substrates. These results reinforce our
suggestion that, although there is absolutely no sequence conser-
vation between CpaB and Lif, these proteins belong to a unique
class of type II secretion, membrane-bound chaperones that pos-
sess evident functional analogies (28, 33, 34).
We demonstrate that soluble periplasmic CpaB lacking its
transmembrane domain is secreted by A. nosocomialis M2
complexed with CpaA. This result agrees with a previous study
that showed that the T2SS chaperone Lif from B. glumae lack-
ing its transmembrane domain (Lifpp) is secreted along with its
target lipase. The study also showed that Lifpp secretion was
dependent on the expression and secretion of its cognate lipase
(34). Altogether, these results suggest that the T2SS substrate–
chaperone complex does not dissociate unless the chaperone is
anchored to the inner membrane. Dissociation of the T2SS
substrate–membrane–anchored chaperone complex is expected
to result in type II-dependent secretion of the substrate and
retention of the chaperone within the periplasmic space. In the
T3SS, the separation of the substrate–chaperone complex is
mediated by the ATPase that powers the system (43). How this
occurs in the T2SS has yet to be elucidated, but we hypothesize
that the membrane anchor in the T2SS chaperone may be
involved in retention of the chaperone and disassembly of the
complex, possibly through an interaction with the T2SS
machinery. The observation that a minimal amount of soluble
CpaB is secreted in the absence of CpaA could be the conse-
quence of a hypothetical interaction between CpaB and the
T2SS.
Because CpaA is a protease, we hypothesized that CpaB
bindingmight inhibit CpaA activity to protect periplasmic pro-
teins from proteolysis. To this end, we assayed human Factor V
cleavage by CpaA alone or in complex with CpaB. We found
that CpaB binding to CpaA does not prevent Factor V cleavage,
suggesting that CpaB is not primarily an immunity protein.
However, we performed an end point assay and thus did not
Figure 8. CpaA remains catalytically active when complexed with CpaB.
Human Factor V was incubated with purified heat-inactivated CpaA-His,
secreted CpaA-His, the secreted CpaA–FLAG–CpaB–His complex, CpaB-His,
or buffer (20 mM HEPES and 150 mM NaCl (pH 7.4)) for 30 min at 37 °C. As a
positive control, Factor V was mixed with thrombin in 25 mM Tris-HCl, 50 mM
NH4Cl, and 5mM CaCl2 (pH 7.4) at 37 °C for 1 h. The rightmost lane represents
thebuffer control for the thrombin reaction. Full-length Factor V is detectable
in the buffer control samples as well as the heat-inactivated CpaA, indicating
a lack of proteolysis. The low-molecular-weight bands corresponding to Fac-
tor V present in the thrombin lane are indicative of Factor V proteolysis. a,
heat-inactivated; b, CpaA-His; c, CpaA-FLAG.
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assess the impact of CpaB binding on the kinetics of CpaA
activity. We have not experimentally measured the stability of
the CpaA–CpaB complex, but the ability to co-purify the com-
plex and the fact that the complex withstands ultracentrifuga-
tion in the analytical ultracentrifugation experiment suggest
that the complex between CpaA and CpaB is very stable. How-
ever, CpaA andCpaBmay still dissociate under our experimen-
tal conditions, and the activity we detected may be due to free
CpaA. For this reason, we cannot conclude that CpaB binding
does not impact CpaA activity but, rather, that the presence of
CpaB does not fully prevent CpaA from cleaving human Factor
V. Furthermore, CpaA was unstable in the absence of CpaB
(supplemental Fig. S5), suggesting that CpaB is involved in fold-
ing CpaA into its active, stable, secretion-competent form.
Here we have characterized CpaA as the first bona fide viru-
lence factor of theA. baumannii–A. calcoaceticus complex and
provided insight into themolecular interactions betweenCpaA
and its T2SS chaperone CpaB. We have demonstrated that the
membrane anchor of CpaB is not required for its chaperone
function and further characterized the novel class of T2SS
chaperonesCpaB represents.Wepropose thatCpaB is involved
in folding of CpaA into its active, stable, secretion-competent
form. It is plausible that the purpose of the transmembrane
domain of CpaB is to retain CpaB in the cell, thus preventing
co-secretion of CpaB with CpaA. Future efforts will focus on
dissecting whether themembrane anchor facilitates an interac-
tion with either SecYEG or the type II apparatus, yielding more
efficient secretion of CpaA. These findings would be beneficial
to public health, as elucidation of T2SS substrates and the
mechanism of secretion could encourage the development of
novel antivirulence treatments for Acinetobacter infections,
which are particularly troublesome because of increasing rates
of multidrug resistance. For instance, specific inhibitors designed
to bind and inhibit the activity and/or secretion of a virulence fac-
tor are a viable option.
Experimental procedures
Strains, plasmids, and growth conditions
The bacterial strains, plasmids, and primers used in this
study are listed in supplemental Tables S1 and S2. All strains
were grown in LB/agar at 37 °C unless specified otherwise.
Antibiotics for E. coli selection were used at the following con-
centrations: 100 g/ml carbenicillin, 5 g/ml tetracycline, 12.5
g/ml chloramphenicol, and 20 g/ml kanamycin. Antibiotics
for A. nosocomialis were used at the following concentrations:
20 g/ml kanamycin, 5 g/ml tetracycline, 12.5 g/ml chlor-
amphenicol, and 200 g/ml carbenicillin. To select for the loss
of sacB, supplementation with 10% sucrose was used.
Generation of bacterial mutants and complementedmutants
Unmarked mutations were made using a method published
previously (37, 44).The In-FusionHDEcoDrycloningkitwasused
in the creation of pGEM-cpaA::kansacB and pGEMcpaAB::
kansacB knockout plasmids, similarly to Refs. 28, 44. Briefly,
1000 bp upstream of the target gene were amplified with
primers 5510015bpkmsacBrev and 5510015bppgem1fw (or
cpaABKOup15bppgemfw2 and cpaABKOup15bpkmsacBrev1),
which produced a product with 15 bp of homology to pGEM
at the 5 end and 15 bp of homology to kmsacB at the 3 end.
1000 bp downstream of the target gene were amplified with
primers 3510015bpkmsacB2fw and 3510015bppgem2rev (or
cpaABKOdw15bppgemrev4 and cpaABKOdw15bpkmsacBfw3),
which produced a product with 15 bp of homology to pGEM at
the 3 end and 15 bp of homology to kmsacB at the 5 end. The
kanamycin resistance cassette and sacB gene were amplified
using primers Kmsacb2rev and Kmsacb1fw. pGEMwas ampli-
fied using primers pgem1rev and pgem2fw. The In-Fusion HD
EcoDry cloning kit was used to fuse the upstream, downstream,
kmsacB, and pGEM fragments together, generating pGEM-
cpaA::kmsacB or pGEM-cpaAB::kmsacB. These plasmids were
introduced to A. nosocomialis through natural transformation
(36). The FLP recombinase plasmid pFLP2 was transiently
introduced into M2 cpaA::kmsacB and M2 cpaAB::kmsacB by
triparentalmating (37) to replace the resistance cassettewith an
frt scar. Strains cpaA and cpaAB were verified by PCR and
sequencing. The cpaA mutation was complemented with the
cpaAB locus (amplified with primers kpnIcpaABrevlocus and
pstIcpaABfwlocus and cloned into pRSM4063 atKpnI andPstI)
under its natural putative promoter using the miniTn7
described in Ref. 44. TheMiniTn7 complementation construct
pRSM4063-pcpaAB was introduced into cpaA through natu-
ral transformation as above. Consistent with the nomenclature
used by Harding et al. (28), mutants designated with “::frt” con-
tain an frt scar in place of the target gene (28).
Generation of pWH1266-based constructs
The In-Fusion EcoDry cloning kit was used to create the
following constructs: pWH-cpaA-flag-cpaB-his, pWH-cpaA-
flag-cpaB, pWH-cpaB-his, andpWH-cpaBpelB-his. pWH-cpaA-
flag-cpaB-his was created by fusing cpaA-flag (amplified with
primers 5cpaAFLAGrev and 3cpaApromfwpwh1), pWH1266
(amplified with 2pwhrev1 and 1pwhfw2), and cpaB-his (ampli-
fied with primers 8CpaBHisrevpwh and 11cpaBfw15bpcpaAF).
pWH-cpaA-flag-cpaB was created by fusing cpaA-flag (ampli-
fied with primers 5cpaAFLAG rev and 3cpaApromfwpwh1) to
pWH1266 (amplified with 2pwhrev1 and 1pwhfw2) and cpaB
(amplified with CpaBrevNT15bppwh2 and 11cpaBfw15bpcpaAF).
pWH-cpaB-his was created by fusing the putative promoter of
cpaAB (amplified with primers 3cpaApromfwpwh1 and
6cpaABpromrev), pWH1266, and cpaB-his (amplified with
primers 8CpaBHisrevpwh and 7CpaBfwpromoverhang). pWH-
cpaBpelB-his was created by fusing pWH1266 to the cpaAB
promoter to cpaBpelB-his, where the N-terminal transmem-
brane domain has been replaced with an N-terminal Sec secre-
tion signal of PelB, (amplified with 8CpaBHisrevpwh and
9CpaBnoTMpelB15bppromfw). All constructs were verified by
PCR and sequencing.
Generation of pBAV-cpaA-flag
CpaA-flag was PCR amplified with 5100fwbamhI and
5100flagrevpstI and cloned into pBAVMCS at PstI and BamH1.
pBAV-cpaA-flag was confirmed by PCR and sequencing.
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Generation of pETDuet-cpaA-his-cpaB and
pET28a-cytocpaB-his
CpaB was PCR-amplified with CpaBcytorevKpnI and CpaB-
cytofwduetNdeI and cloned intomultiple cloning site 2 at KpnI
and NdeI. CpaA was cloned into pETDuet using the In-Fusion
HD EcoDry cloning kit using petDuetfwinfuse and petDuet-
revinfuse to amplify pETDuet-cpaB and CpaAcytofwduet15bp
and CpaAcytoHisrevduet15bp to amplify cpaA with 15 bp of
homology to pETDuet. The pETDuet-cpaA-his-cpaB was con-
firmed through PCR and sequencing.
Cyto-cpaBwasPCR-amplifiedwith15bpofhomologyon the5
and 3 ends to pET28awithCytocpaBrev andCytoCpaBfw. Cyto-
cpaB was cloned into pET28a in-frame with the C-terminal
histidine tag using the In-Fusion HD EcoDry cloning kit using
Pet28ahisfw and Pet28auprev. pET28a-cyto-cpaB-hiswas con-
firmed by sequencing.
Generation of polyclonal rabbit sera against CpaA
The pETDuet vector was used to overexpress CpaA and
CpaB in the cytoplasm of E. coli Rosetta 2 cells for purification.
1 liter of LBwas inoculated fromanovernight culture of Rosetta
2/pETDuet-cpaA-his-cpaB at 0.05 A/ml, grown to mid-log
phase, and induced with 1 mM isopropyl 1-thio--D-galactopy-
ranoside. The culture was grown for an additional 4 h. Cells
were harvested at 8000 rpm for 10min. Cells were washed with
30 mM Tris (pH 8) and resuspended in 40 ml of 50 mM
NaH2PO4, 300 mM NaCl, and 10 mM imidazole (pH 8). Cells
were lysed with a cell disruptor using two rounds at 35,000 p.s.i
(Constant System Ltd., Kennesaw, GA). Cell lysates were clar-
ified at 11,000 rpm for 30 min. Cell lysates were passed over a
nickel-NTA agarose column (Gold Bio, St. Louis, MO). The
load fraction is the total cell lysate. The flow-through was col-
lected as what passed through the column and did not bind the
nickel-NTA resin. The columnwaswashedwith 20ml of 50mM
NaH2PO4, 300 mM NaCl, and 25 mM imidazole (pH 8) and 20
ml of 50mMNaH2PO4, 300mMNaCl, and 50mM imidazole (pH
8) (45). Proteins were eluted with 50 mM NaH2PO4, 300 mM
NaCl, and 250 mM imidazole (pH 8). Elution fractions were
analyzed by SDS-PAGE analysis and Coomassie staining. The
polyacrylamide gel band corresponding to CpaA-His was sent
to Abore Inc. (Ramona, CA) for peptide extraction and devel-
opment of rabbit-derived polyclonal antibodies.
Nickel-NTA affinity purification of CpaB-His and CpaA-FLAG
Cultures of M2 cpaAB carrying pWH-pCpaA-flag-cpaB-
his, pWH-pCpaA-flag-cpaB, or pWH1266 were grown over-
night. Cells were pelleted at 10,000  g for 10 min. Cells were
washed with 30 mM Tris (pH 8) and resuspended in 15 ml of 50
mMNaH2PO4, 300mMNaCl, and 10mM imidazole (pH8). Cells
were lysed with a cell disruptor using two rounds at 35,000 p.s.i.
(Constant System Ltd.). Cell lysates were incubated with 0.05%
Triton X-100 and rolling at 4 °C for 1 h to solubilize CpaB-His
(46). Cell lysates were clarified at 11,000 rpm for 30 min. Cell
lysates were passed over a nickel-NTA-agarose column (Gold
Bio). The load fraction is the total cell lysate. The flow-through
was collected as what passed through the column and did not
bind the nickel-NTA resin. The columnwas washed with 20ml
of 50mMNaH2PO4, 300mMNaCl, and 25mM imidazole (pH 8)
and 20 ml of 50 mMNaH2PO4, 300 mMNaCl, and 50 mM imid-
azole (pH 8) (45). Proteins were eluted with 50 mM NaH2PO4,
300 mM NaCl, and 250 mM imidazole (pH 8). Load, flow-
through, wash, and elution fractions were analyzed byWestern
blot analysis probing for CpaA-FLAG and CpaB-His.
Size-exclusion purification of CpaA and CpaB
CpaA-His and CpaB were co-purified from E. coli Rosetta 2
cells by nickel-NTA resin as described above. The nickel-NTA
elution was further purified by a Superdex 200 Prepgrade size-
exclusion column (GEHealthcare) with 10mMHEPES (pH 7.4)
and 150 mM NaCl. The fractions under the CpaA–CpaB com-
plex peakwere concentrated using anAmiconUltra centrifugal
filter (Millipore) with a 10-kDa molecular mass cutoff.
Analytical ultracentrifugation of the CpaA–CpaB complex
Sedimentation equilibrium experiments were performed in a
Beckman/Coulter XL-A analytical ultracentrifuge using an
An60Ti rotor at 10 °C with size-exclusion–purified CpaA–
CpaB complex at concentrations of 4.2 M, 3.4 M, and 2.5 M.
Data were obtained at speeds of 7000, 8000, and 9000 rpm. A
partial specific volume for CpaA–CpaB of 0.7321 was calcu-
latedwith Sednterp (47), and a global fit analysis was performed
in Ultrascan II version 9.9 (38). The molecular mass reported is
the mean  S.D. of the three independent experiments at all
concentrations and speeds analyzed.
CpaB-His localization and limited proteolysis of
A. nosocomialis M2 spheroplasts
Overnight cultures of A. nosocomialis M2 carrying pWH-
cpaB-his or pWH-cpaBpelB-his were used to inoculate LB sup-
plemented with tetracycline that were grown at 37 °C and 225
rpm. Periplasmic and spheroplast preparations were done as
reported previously (39). Briefly, cultures grown to 0.5 A/ml
were pelleted by centrifugation at 10,000 rpm for 10 min. Cells
were resuspended at 1A/50l in 20% sucrose, 30 mMTris-HCl
(pH 8.0), 1 mM EDTA, and 1 mg/ml lysozyme (Gold Bio) and
incubated on ice for 2 h. Spheroplasts were pelleted at 16,000
g for 5 min. The supernatant fraction was considered the
periplasmic fraction. For CpaB-His localization, periplasmic
and spheroplast fractions were analyzed by SDS-PAGE and
immunoblotting. Proteolysis of spheroplasts was performed as
follows. Spheroplasts were resuspended at 0.01 A/l in 0.5
mg/ml proteinase K (Sigma) in 30 mM Tris-HCl (pH 8.0) and
incubated at 56 °C for 0–20 min. Protease activity was stopped
by the addition phenylmethylsulfonyl fluoride and 4 Laemmli
buffer and boiling at 100 °C. The equivalent of 0.1 A of each
sample was resolved by SDS-PAGE and analyzed by Western
blotting, probing for CpaB-His and RNA polymerase as a cyto-
plasmic control.
Immunoblotting
Bacterial secretion whole-cell and supernatant samples were
prepared as published previously (28, 48). Briefly, cultures were
grown to 0.5A/ml, and 0.5Awas pelleted by centrifugation and
resuspended in 50 l of 1 Laemmli buffer for the whole-cell
samples. Supernatant samples were obtained by TCA-precipi-
tating cell-free supernatants as published previously (48). Pro-
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teins were resolved by SDS-PAGE analysis and transferred to a
nitrocellulose membrane by semidry transfer and probed with
either monoclonal anti-FLAG (1:2000, Sigma), polyclonal anti-
histidine (1:2000, Pierce), polyclonal anti-CpaA (1:1000, this
study), and/ormonoclonal anti-RNApolymerase (1:2000, Neo-
clone).Western blots were probed with IRDye-conjugated sec-
ondary antibodies and visualized with an Odyssey CLx imaging
system (LI-COR Biosciences, Lincoln, NE).
G. mellonella infection
G. mellonella infections withA. nosocomialisM2,gspD::frt,
cpaA::frt, and the complemented strains were done as pub-
lished previously (28). Cultures were grown in LB to 0.5 A/ml.
Cells were pelleted by centrifugation, washed with sterile PBS,
and resuspended in PBS.G. mellonellawere injected with 10l
of eitherM2,gspD::frt,cpaA, or the complemented strains at
an inoculum of 1 107. Infected larvae were incubated at 37 °C
and monitored for viability over time. Larvae were considered
dead when they did not respond to touch.
Mousemodel of pneumonia
The Vanderbilt UniversityMedical Center Institutional Ani-
mal Care and Use Committee approved the infection experi-
ments. Jackson Laboratories wild-type C57BL/6 mice were
infected with either the cpaA or the cpaA complemented
strain as published previously (28). Nine-week-old male mice
were inoculated intranasally with 1 109 cfus. Thirty-six hours
post-infection, mice were euthanized, and lung, liver, spleen,
and heart tissues were homogenized and dilution-plated to
determine colony-forming units. Median colony-forming unit
counts from each mouse are reported and were analyzed by
Mann Whitney non-parametric tests using GraphPad Prism 6
(GraphPad Software Inc., La Jolla, CA).
Factor V cleavage assay
CpaA-His or CpaA-FLAG-CpaBpelB-His was purified out of
the supernatant ofA. nosocomialisM2. Briefly,A. nosocomialis
M2 carrying pWH-cpaA-his-cpaB orA. nosocomialiscpaAB::frt
carrying both pBAV-cpaA-flag and pWH-cpaBpelB-his was
grown in LB supplemented with tetracycline or kanamycin and
tetracycline to mid-log phase. CpaA-His or the CpaA-FLAG-
CpaBpelB-His complex was purified from cell-free supernatants
through nickel affinity chromatography as above. CpaB-His
was purified from cell lysate of E. coli Rosetta 2 cells carrying
pET28-cpaB-his. Cells were grown overnight at 30 °C and 225
rpm in autoinduction medium supplemented with kanamycin.
Cells were harvested and lysed as described above. CpaB-His
was purified by nickel affinity chromatography as above. The
purified proteins were concentrated, and the buffer was
changed to 20 mMHEPES, 150 mMNaCl, and 50% glycerol (pH
7.4) using Amicon Ultra centrifugal filter units.
The Factor V cleavage assay was carried out according to
Tilley et al. (29) with modifications. Briefly, 1.6 g of purified
CpaA or CpaB (in 20 mM HEPES, 150 mM NaCl, and 50% glyc-
erol (pH7.4)) wasmixedwith 11 ng of human FactorV (Abcam,
Cambridge, MA) in a total volume of 20 l (20 mM HEPES and
150 mM NaCl (pH 7.4)). Heat-inactivated CpaA was incubated
at 100 °C for 20 min prior to the addition of Factor V. Based on
Coomassie staining indicating that CpaA and CpaB form a 1:1
complex, 3.2 g of the CpaA–CpaB complex was used in the
assay, which is estimated to contribute 1.6 g of CpaA. All
samples were incubated at 37 °C for 30 min.
-Thrombin was used as a positive control in the proteolytic
cleavage of Factor V (49). The thrombin-catalyzed digestion of
FV was carried out as described previously (50) with modifica-
tions. Briefly, 0.6 mg/ml human Factor V and 2 g/ml of
-thrombin (Thermo Fisher, Waltham, MA) in 25 mM Tris-
HCl (pH 7.4), 50 mM NH4Cl, and 5 mM CaCl2 was incubated at
37 °C for 60 min. The buffer control for this reaction was car-
ried out in the same way but in the absence of -thrombin.
Factor V cleavage was monitored by Western blotting by
resolving 8.2 ng of Factor V per lane on an 8% polyacrylamide
gel. Factor V was detected using polyclonal sheep anti-human
Factor V (Thermo Fisher, 1:1000), polyclonal rabbit anti-sheep
Ig (Fc-specific, Sigma-Aldrich, St. Louis, MO, 1:12,000), and
IRDYE800CW goat anti-rabbit IgG (LI-COR, 1:15,000). CpaA-
His was detected with monoclonal mouse anti-His6 (Thermo
Fisher, 1:1000) and IRDYE680RD goat anti-mouse IgG (LI-
COR, 1:15,000), whereas CpaA-FLAG was detected using
monoclonalmouse anti-FLAGM2 (Sigma-Aldrich, 1:1000) and
IRDYE680RD goat anti-mouse IgG (LI-COR).
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Interaction between CpaA and chaperone CpaB

















Figure S1-A. nosocomialis CpaA Secretion is Dependent upon cpaA. Supernatants from wildtype M2, 
ΔcpaA, and the complemented strains (cpaA+) were analyzed by Western blot analysis probing for CpaA 
and RNA polymerase for secretion of CpaA. CpaA is detected in the supernatants of wildtype M2 and the 
complemented ΔcpaA strain, indicating CpaA secretion is dependent upon cpaA. RNA polymerase was 
used as a lysis control. RNA polymerase is not detected; indicating CpaA is actively secreted by A. 
nosocomialis.  
 
Figure S2- M2 CpaB is Required for Secretion of CpaA-His but Deletion of cpaA and cpaB does Not 
Affect Secretion of Type II Substrate LipH-His. Western blot analysis on whole cell (W) and cell free 
supernatant (S) fractions of (A) wildtype M2 or (B) ΔcpaAB M2 expressing empty vector, pWH-lipH-his, 
pWH-cpaA-his, or pWH-cpaA-hiscpaB probing for CpaA-His or LipH-His. All strains and fractions were 
probed for RNA polymerase as a cell lysis control. CpaA-His secretion was detected in strains carrying 
pWH-cpaA-his or pWH-cpaA-hiscpaB. CpaA-His secretion was only detected in cells expressing cpaB. 
LipH-His expression and secretion was detected in cells carrying pWH-lipH-his. CpaA and CpaB are not 









Figure S3-Replacement of the N-terminal Transmembrane Domain of CpaB with a Sec Secretion 
Signal Results in a Soluble Periplasmic Construct of CpaB. Western blot analysis on M2 cells 
fractionated into the periplasm (peri) or spheroplast (sphero) expressing empty vector, pWH-cpaB-his or 
pWH-cpaBpelB-his probing for CpaB-His and RNA polymerase as a lysis control. CpaB-His is detected in 
the spheroplast fraction of the cells expressing full length CpaB. CpaB-His is detected in the spheroplast 
and periplasmic fractions of cells expressing the soluble cpaBpelB construct where the N-terminal 
transmembrane domain has been replaced with a Sec secretion signal.  
 
Figure S4-CpaA is Required for Efficient Secretion of Soluble Periplasmic CpaB. Western blot 
analysis on whole cell (W) and cell free supernatant (S) fractions of ΔcpaAB M2 expressing empty vector, 
pWH-cpaB-his, pWH-cpaBpelB-his or pWH-cpaBpelB-his and pBAV-cpaA-flag was probed for CpaB-His. 
All fractions were probed for RNA polymerase as a lysis control. CpaB-His was detected in all cells 
carrying pWH-cpaB-his or pWH-cpaBpelB-his. A low level of CpaB-His secretion was detected in the 
absence of CpaA in cells carrying pWH-cpaBpelB-his. Cells carrying pBAV-cpaA-flag efficiently secreted 









Figure S5-CpaA is Unstable and Degraded in the Periplasm in the Absence of CpaB. Whole cells 
(WC), spheroplasts (sphero), periplasmic (peri) and supernatant (sup) preparations of A. nosocomialis M2 
wildtype (wt), ΔcpaB mutant, and cpaB+ complemented strains were analyzed by Western blot using 
anti-CpaA polyclonal antibodies. RNA polymerase was used as a lysis control. The asterisk indicates the 





































Supplemental Table 1 




pBAV-cpaA-flag This study 
pET28a Novagen 
pET28a-cpaB-his This study 
pETDUET Novagen 
pETDUET-cpaA-his-CpaB This study 
pFLP2 (51)  
pGEM-cpaA::kansacB This study 
pGEM-cpaAB::kansacB This study 
pRSM4063 (44)  
pRSM4063-pcpaA This study 
pWH1266 (52) 
pWH-cpaA-his (28)  
pWH-cpaA-his-cpaB (28)  
pWH-lipH-his (28) 
pWH-cpaA-flag-cpaB This study 
pWH-cpaA-flag-cpaB-his This study 
pWH-cpaB-his This study 
pWH-cpaB-pelB-his This study 
Strains  
A. nosocomialis M2 (38, 53)  
A. nosocomialis M2 ΔgspD::frt 
A. nosocomialis M2 ΔcpaB::frt 
(28) 
       (28) 
A. nosocomialis M2 
ΔcpaA::frt 
This study 
A. nosocomialis M2 
ΔcpaAB::frt 
This study 
A. nosocomialis M2 
ΔcpaA::frt (cpaAB+) 
This study 
E. coli Rosetta 2 Novagen 
A. baumannii RUH134 (54) 
A. baylyi ADPI (55) 
A. baumannii SDF (56) 
A. baumannii AYE (56) 
A. baumannii AB5075 (57) 
A. baumannii AB04 (58) 
A. baumannii AB004 (29) 
A. baumannii AB005 (29) 
A. baumannii AB006 (29) 
A. baumannii AB007 (29) 
A. baumannii AB008 (29) 
A. baumannii AB009 (29) 
A. baumannii AB010 (29) 
A. baumannii AB011 (29) 
A. baumannii AB012 (29) 
A. baumannii AB013 (29) 
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A. baumannii AB014 (29) 
A. baumannii AB033 (29) 
A. baumannii AB034 (29) 
A. baumannii AB028 (29) 
A. pittii 31205 (59) 
A. calcoaceticus 27693 (59) 
A. pittii 28207 (59) 
A. pittii 30005 (59) 
A. pittii 31975 (59) 
A. pittii 31357 (59) 
A. pittii 33632 (59) 
A. pittii 32493 (59) 
A. nosocomialis 26959 (59) 
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Primers used in this study 
Description Sequence 
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